BioLargo CEO Dennis Calvert Elaborates on the Importance of its new Engineering Division and Financing to Accelerate Commercialization

Phoenix, AZ, Sept. 20, 2017 -- Dennis Calvert, CEO of BioLargo, Inc. (OTCQB: BLGO) was interviewed on the Uptick Network Stock Day Podcast with host Everett Jolly. In the interview Mr. Calvert explained the importance of the recent addition of their full service engineering division to the company. The new subsidiary represents the addition of significant talent, numerous commercial opportunities and the capability to complete engineering & scale up of its AOS advanced water treatment technology. Continuing the interview, Mr. Calvert discussed the financing arrangement with Lincoln Park Capital and how this capital will supplement BioLargo’s continued growth. Furthermore, Mr. Calvert provided a brief update on the commercial progress of its Cupridyne Clean industrial odor control products, and finished by discussing the pending FDA applications for its Clyra Medical products that will provide commercial solutions in the infection control, chronic wound therapy, and regenerative tissue therapy markets.

In closing Mr. Calvert states, “At BioLargo, we are continuously innovating to help ‘Make Life Better’. We have successfully assembled an exceptional team of highly qualified people to surround our world-class technology and procured additional capital resources to help accelerate commercialization on all fronts.”

To listen to the full interview please click here or the following link: https://upticknewswire.com/featured-interview-ceo-dennis-calvert-of-biolargo-inc-otcqbblgo-3

About BioLargo, Inc. 
BioLargo, Inc. is a sustainable science and technology company that makes life better by delivering award-winning products for clean water, clean air and advanced wound care. More information can be found about the company and its subsidiaries at www.BioLargo.com. Its subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo's subsidiary Odor-No-More Inc., features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that must contend with malodors, VOC’s or similar air quality related problems. Its personal care products are finding adoption through white labeling or early market entry in the pet, equine, military supply and consumer markets, and include the Nature's Best Solution® and Deodorall® brands (www.OdorNoMore.com). BioLargo's subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced wound care management featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc.

Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K.

Source: Uptick Newswire

Contact:
Company Contact
Dennis Calvert
President and CEO
BioLargo, Inc.
949-643-9540 x2